New clinical trial to determine recommended dose of antibody when combined with sorafenib in patients with hepatocellular carcinoma (HCC)

doctor and patient

A new clinical trial testing the combination of an antibody, TRC105, with sorafenib, a multikinase inhibitor, is now open for patients with hepatocellular carcinoma (HCC), a type of liver cancer. TRC105 is an antibody that affects the ability of tumors to grow new blood vessels. The purpose of this trial is to determine the recommended dose of TRC105 when combined with sorafenib. Tim Greten, M.D., Thoracic and Gastrointestinal Oncology Branch, is leading NCI’s participation with Tracon Pharmaceuticals. For more information about this trial, please visit:

Summary Posted: Sat, 04/01/2017